1
Clinical Trials associated with PEV7C1(Pevion Biotech)A Phase I Randomized Placebo Controlled Study of a Virosome Formulated Anti-Candida Vaccine (PEV7) Administered by the Vaginal (PEV7C) or Intramuscular (PEV7B) Route to Healthy Adult Volunteers
Pevion Biotech develops a state-of-the-art vaccine against recurrent vulvovaginal candidiasis (RVVC) caused by the pathogenic form of Candida albicans especially in pre-menopausal women of childbearing age with a history of recurrent vulvovaginal candidiasis. This study is designed to evaluate the safety and tolerability of the vaccine, administered by two different routes (intramuscular and intravaginal) as primary endpoint. Immunogenicity will be evaluated as secondary endpoint.
100 Clinical Results associated with PEV7C1(Pevion Biotech)
100 Translational Medicine associated with PEV7C1(Pevion Biotech)
100 Patents (Medical) associated with PEV7C1(Pevion Biotech)
100 Deals associated with PEV7C1(Pevion Biotech)